Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital East
iTMS Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age 18 years or older at the time of obtaining consent 2) Participants with resectable clinical stage I -III non-small cell lung cancer 3) The following treatments are planned at the participating institutions: Cohort A : Neoadjuvant treatment cohort Cohort B: Up-front surgery Cohort 4) ECOG Performance Status of 0 or 1 5) Written informed consent has been obtained from the participant for participation in this study.
Exclusion criteria
Exclusion criteria: 1)Presence of active co-occurring malignancies 2) Pregnant 3) Have undergone hematopoietic stem cell transplantation 4) Any other cases deemed unsuitable for inclusion in this study by the principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation of molecular profiles, including genetic abnormalities, RNA expression, immune cell phenotypes, and minimal residual disease (MRD) in peripheral blood and tumor tissue with recurrence and prognosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationships among molecular profiles, treatment outcomes, clinical-pathological factors such as treatment course, imaging findings, and pathological observations. | — |
Countries
Japan
Contacts
Public ContactKotaro Nomura
National Cancer Center Hospital East Department of Thoracic Surgery
Outcome results
None listed